BICYCLE THERAPEUTICS PLC - Common Stock, par value $0.004 per share ("Shares") (BCYC)

Historical Holders from Q2 2019 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.004 per share ("Shares")
Symbol
BCYC on Nasdaq
Shares outstanding
22,866,677
Price per share
$7.08
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
36,906,185
Total reported value
$285,619,779
% of total 13F portfolios
0%
Share change
-4,294,502
Value change
-$29,768,237
Number of holders
99
Price from insider filings
$7.08
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BICYCLE THERAPEUTICS PLC - Common Stock, par value $0.004 per share ("Shares") (BCYC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Forbion Growth Opportunities Fund II Cooperatief U.A. 7.3% $28,343,629 3,452,330 Forbion Growth Opportunities Fund II Cooperatief U.A. 21 Nov 2024
WESTFIELD CAPITAL MANAGEMENT CO LP 5.5% $21,430,867 2,610,337 Westfield Capital Management Company, L.P. 31 Dec 2024
ARMISTICE CAPITAL, LLC 10% $18,275,048 2,284,381 Armistice Capital, LLC 30 Jun 2025
Point72 Asset Management, L.P. 3.9% -49% $14,882,536 -$15,032,008 1,860,317 -50% Point72 Asset Management, L.P. 30 Jun 2025
Deep Track Capital, LP 2.4% -54% $9,625,952 -$12,943,416 1,203,244 -57% Deep Track Capital, LP 30 Jun 2025
As of 30 Sep 2025, BICYCLE THERAPEUTICS PLC - Common Stock, par value $0.004 per share ("Shares") (BCYC) has 99 institutional shareholders filing 13F forms. They hold 36,906,185 shares. .

Top 25 institutional shareholders own 152% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BAKER BROS. ADVISORS LP 48% 10,885,357 0% 0.61% $84,252,663
FCPM III SERVICES B.V. 15% 3,452,330 0% 5.3% $26,721,034
ARMISTICE CAPITAL, LLC 13% 2,978,000 +6.4% 0.72% $23,049,720
WESTFIELD CAPITAL MANAGEMENT CO LP 13% 2,952,543 +6.2% 0.1% $22,852,683
Siren, L.L.C. 8.8% 2,012,752 0% 0.61% $15,578,700
Long Focus Capital Management, LLC 6.2% 1,418,695 +7.7% 0.64% $10,980,699
PRICE T ROWE ASSOCIATES INC /MD/ 6.1% 1,384,794 -5.7% 0% $10,719,000
ACADIAN ASSET MANAGEMENT LLC 5.7% 1,314,556 +88% 0.02% $10,155,000
Candriam S.C.A. 5.1% 1,172,387 0% 0.05% $9,074,275
PRINCIPAL FINANCIAL GROUP INC 5% 1,148,402 +65% 0% $8,888,631
MILLENNIUM MANAGEMENT LLC 4.6% 1,054,746 -27% 0.01% $8,163,734
MORGAN STANLEY 3.6% 822,705 -21% 0% $6,367,736
BANK OF AMERICA CORP /DE/ 2.6% 591,535 -29% 0% $4,578,482
RENAISSANCE TECHNOLOGIES LLC 2.3% 518,700 +63% 0.01% $4,014,738
SILVERCREST ASSET MANAGEMENT GROUP LLC 2.1% 476,976 +80% 0.02% $3,691,794
Point72 Asset Management, L.P. 1.9% 430,900 -76% 0.01% $3,335,166
Jefferies Financial Group Inc. 1.8% 401,926 -13% 0.03% $3,110,907
BlackRock, Inc. 1.2% 282,418 +6.8% 0% $2,185,916
Palo Alto Investors LP 0.97% 221,071 -11% 0.32% $1,711,090
Legal & General Group Plc 0.87% 197,917 +13% 0% $1,531,879
PINNACLE ASSOCIATES LTD 0.86% 196,618 +14% 0.02% $1,521,823
Eversept Partners, LP 0.85% 194,440 -8.1% 0.12% $1,504,966
CITADEL ADVISORS LLC 0.83% 189,027 +36% 0% $1,463,069
PLATINUM INVESTMENT MANAGEMENT LTD 0.81% 184,603 -35% 0.09% $1,428,827
TWO SIGMA INVESTMENTS, LP 0.81% 184,537 +228% 0% $1,428,316

Institutional Holders of BICYCLE THERAPEUTICS PLC - Common Stock, par value $0.004 per share ("Shares") (BCYC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 1,386 $9,813 -$5,168 $7.08 1
2025 Q3 36,906,185 $285,619,779 -$29,768,237 $7.74 99
2025 Q2 41,200,406 $286,338,478 -$7,404,258 $6.95 110
2025 Q1 41,735,285 $354,350,748 -$8,366,393 $8.49 95
2024 Q4 41,890,221 $586,472,317 -$21,543,705 $14.00 96
2024 Q3 40,439,351 $915,266,321 +$21,080,974 $22.63 104
2024 Q2 39,722,044 $803,959,492 +$167,237,644 $20.24 105
2024 Q1 30,475,266 $758,677,656 +$6,974,793 $24.90 93
2023 Q4 31,374,408 $567,252,558 -$28,664,876 $18.08 98
2023 Q3 32,418,922 $651,281,538 +$165,201,151 $20.09 101
2023 Q2 24,236,173 $618,449,426 +$18,484,148 $25.52 84
2023 Q1 23,558,818 $498,895,905 -$47,151,037 $21.27 89
2022 Q4 23,577,228 $697,847,861 +$39,624,167 $29.60 87
2022 Q3 23,196,999 $539,598,338 +$13,911,506 $23.26 77
2022 Q2 22,709,672 $381,075,755 -$69,885,312 $16.78 78
2022 Q1 20,168,148 $884,247,452 -$137,175,184 $43.88 100
2021 Q4 21,550,279 $1,311,636,981 +$387,558,387 $60.87 98
2021 Q3 14,210,499 $591,072,741 +$80,484,868 $41.59 67
2021 Q2 12,412,613 $376,901,461 +$30,169,498 $30.36 53
2021 Q1 11,420,830 $341,203,000 +$123,064,104 $29.87 39
2020 Q4 7,328,435 $131,544,000 -$3,975,466 $17.95 27
2020 Q3 7,550,163 $143,830,000 +$24,085,212 $19.05 18
2020 Q2 6,287,737 $98,861,000 +$4,298,929 $15.74 15
2020 Q1 5,977,254 $81,901,000 +$1,078,206 $13.65 12
2019 Q4 5,901,993 $55,657,000 -$6,870,216 $9.43 8
2019 Q3 6,446,149 $73,420,000 -$1,907,302 $11.39 11
2019 Q2 6,635,216 $66,751,000 +$66,751,000 $10.06 14